Afrin is a nasal decongestant spray for adults and children aged 6 years and over. Its active ingredient, oxymetazoline hydrochloride, provides short-term relief by narrowing swollen blood vessels in the nose.
Afrin is a nasal decongestant spray containing oxymetazoline hydrochloride 0.05%. It is intended for adults and children aged 6 years and over with temporary nasal blockage from colds, hay fever, sinus congestion, or other upper-airway irritation. Oxymetazoline narrows swollen blood vessels inside the nose, helping air move more freely.
Afrin is supplied as a 15 ml nasal spray. Each millilitre contains oxymetazoline hydrochloride 0.05%. The dose is stated on the pack — follow the leaflet.
Oxymetazoline acts mainly on alpha-adrenergic receptors in the nasal lining. These receptors control the diameter of small blood vessels. When vessels contract, fluid leakage and tissue swelling fall, creating more space for airflow through the nostrils [1].
Afrin is used intranasally. The usual dose for adults and children aged 6 years and over is two or three sprays into each nostril every 10 to 12 hours, with a maximum of two doses within 24 hours.
Use Afrin for no more than three consecutive days.
Do not exceed the recommended frequency. More sprays do not produce a better result and can raise the chance of rebound congestion, dryness, palpitations, or raised blood pressure.
If a dose is missed, use Afrin only when congestion returns and the next permitted dosing interval has passed. Do not double the number of sprays.
The effect commonly begins within minutes. It may last for up to 12 hours. This duration can make Afrin useful before sleep or during travel.
The NHS advises limiting decongestant sprays because regular use beyond several days can make nasal congestion harder to settle [3].
Afrin works locally in the nasal passages rather than treating the virus, allergen, or inflammation that caused the congestion. Oxymetazoline constricts superficial blood vessels in the nasal mucosa, reducing swelling and the sensation of pressure.
Extended use can produce rebound congestion, also called rhinitis medicamentosa. The nasal lining becomes dependent on the decongestant effect, and blockage may return more strongly as the spray wears off. The National Library of Medicine describes this as a recognised risk with repeated topical vasoconstrictor use [2].
It is intended for adults and children aged 6 years and over with temporary nasal blockage from colds, hay fever, sinus congestion, or other upper-airway irritation.
It can also help when congestion makes it difficult to breathe through the nose. Afrin does not clear mucus from the chest, treat bacterial sinus infection, or replace allergy treatment where allergies are the underlying cause.
Afrin is one option for short-term nasal blockage. The best approach depends on whether the main problem is a cold, allergy, thick mucus, sinus pressure, or repeated congestion.
| Option | Main action | Suitable role |
|---|---|---|
| Oxymetazoline nasal spray | Shrinks swollen nasal blood vessels | Fast, short-term relief of marked blockage |
| Xylometazoline nasal spray | Shrinks swollen nasal blood vessels | Short-term decongestion with similar rebound risk |
| Saline spray or rinse | Moisturises and clears mucus | Frequent use for dryness, mucus, allergens, and mild congestion |
Oxymetazoline and xylometazoline work in similar ways. Neither should be used continuously for longer than a few days. Saline products do not cause medication-related rebound congestion, though they may feel less powerful when the nose is severely swollen.
For persistent allergic rhinitis, clinicians often favour an intranasal corticosteroid because it reduces inflammation over time. It does not usually provide the near-immediate opening effect of Afrin. This difference matters: Afrin helps the swollen blood vessels; corticosteroid sprays target inflammatory activity.
Afrin is not for you if you have had an allergic reaction to oxymetazoline or another component of the spray.
Extra caution is needed with:
Oxymetazoline should not be combined with monoamine oxidase inhibitors, often called MAOIs, or used within 14 days of stopping them. This combination may increase the risk of a dangerous rise in blood pressure. Tricyclic antidepressants and some medicines used for Parkinson’s disease can also intensify sympathomimetic effects.
Pregnancy and breastfeeding require individual medical advice because nasal decongestants can affect blood vessels beyond the nose. The MHRA encourages careful medicine selection during pregnancy, including for products used without a prescription.
Avoid using Afrin in children under 6 years old. Accidental overuse of topical decongestants can cause serious drowsiness, slowed breathing, blood-pressure changes, or heart-rate changes in young children.
If you have high blood pressure, heart disease, thyroid problems, diabetes, glaucoma, prostate-related difficulty passing urine, or damaged nasal tissue, ask a healthcare professional before using it.
Most people tolerate short courses of Afrin without significant problems. Local effects are the most common and may include transient burning, stinging, dryness, sneezing, or irritation inside the nose.
Possible side effects include:
Systemic effects are uncommon when Afrin is used at the recommended dose, though oxymetazoline can be absorbed through the nasal lining. People with cardiovascular disease or sensitivity to stimulants may notice these effects more readily.
Stop using Afrin and seek urgent medical assessment for chest pain, severe dizziness, fainting, facial swelling, wheezing, or a rapid irregular heartbeat. Persistent one-sided blockage, high fever, worsening facial pain, or symptoms lasting beyond a typical cold also need assessment because a decongestant will not treat every cause of nasal obstruction.
The most frequent mistake is continuing Afrin after the third day because the nose feels blocked again. This often reflects rebound congestion rather than a need for more spray.
Other errors include:
A second common issue is blaming the spray when a cold naturally fluctuates. Congestion often changes during the day due to lying down, dry indoor air, temperature changes, and mucus movement. Afrin can improve airflow, yet it cannot prevent the normal course of a viral cold.
In clinical practice, doctors often see Afrin as a useful short-course option when nasal blockage is interfering with sleep, eating, or short-term daily comfort. The expected benefit is easier nasal breathing, not treatment of the underlying cold or allergy.
A clinician will usually focus on duration of use first. Three days is a practical boundary because it reduces the chance that temporary relief becomes rebound congestion. Doctors also look for patterns that suggest another condition, such as recurrent sinus symptoms, allergy-driven blockage, nasal polyps, or medication-related congestion.
The European Medicines Agency evaluates nasal medicines with attention to local tolerability and systemic exposure. For Afrin users, the practical message is simple: keep treatment short, use the smallest helpful amount, and avoid repeated dosing for weeks.
Afrin can begin reducing nasal swelling within minutes because oxymetazoline acts directly on blood vessels in the nasal lining. Its effect may last up to 12 hours, which is why dosing is limited to twice a day. The FDA Drug Facts information for oxymetazoline sprays has long described temporary relief of nasal congestion with this type of medicine. The FDA label revision cited for Afrin was issued in 2016 [4].
Afrin should be used for no more than three consecutive days. Longer use raises the likelihood of rebound congestion, where the nose blocks again as the effect wears off. NHS guidance published in 2023 advises that decongestant nasal sprays should not be used for more than about a week, while Afrin’s own oxymetazoline directions use a stricter three-day limit. The shorter limit is the sensible choice for avoiding dependency on nasal vasoconstriction.
Afrin can temporarily ease a severely blocked nose during hay fever, but it does not control the allergic inflammation driving the symptoms. Sneezing, itchy eyes, watery discharge, and repeat seasonal congestion often respond better to allergy-focused treatment. The WHO-supported ARIA framework, first published in 2001, emphasises reducing allergen-driven inflammation rather than relying on repeated decongestant use. Reserve Afrin for short periods when nasal swelling is the main issue.
Oxymetazoline is designed to work locally, yet some absorption can occur through the nasal lining. People with hypertension, coronary disease, hyperthyroidism, or an irregular heartbeat may be more sensitive to palpitations or blood-pressure changes. The MHRA’s medicine-safety approach in 2024 continues to place extra emphasis on checking sympathomimetic medicines in people with cardiovascular risk factors. Avoid exceeding the recommended dose or frequency.
Afrin must not be used with MAOI antidepressants or within 14 days after stopping an MAOI. These medicines can amplify the blood-pressure effects of sympathomimetic decongestants. Tricyclic antidepressants may also increase sensitivity to oxymetazoline in some people. The National Library of Medicine’s 2024 clinical monograph on oxymetazoline lists relevant interaction and cardiovascular precautions [5].
Stop extending the course of Afrin, even if the blocked feeling is frustrating. Saline spray or nasal irrigation can reduce dryness and help clear mucus while the nasal lining settles. If severe congestion continues, especially with facial pain, fever, recurrent nosebleeds, or symptoms lasting more than 10 days, medical assessment is appropriate. The EMA’s 2014 guideline on the quality of nasal medicinal products recognises that local nasal tolerability is central to appropriate spray use.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
